Humacyte terminates stock sale agreement with Jefferies

Humacyte Inc. (NASDAQ: HUMA) terminated its stock sale agreement with Jefferies LLC, the company announced. The termination notice was delivered on November 21, 2025, and will become effective 10 days later under the agreement terms.

The Open Market Sale Agreement, originally entered into on September 1, 2022, allowed Humacyte to sell up to $80 million of its common stock through Jefferies acting as agent. The company stated it faces no termination penalties related to ending the agreement.

Under the agreement, Humacyte could offer and sell shares of its common stock with a par value of $0.0001 per share from time to time during the agreement term. The original agreement was filed as an exhibit to the company's Form S-3 registration statement with the Securities and Exchange Commission on September 1, 2022.

The company provided no additional details regarding the reasons for the termination or future equity financing plans.

You May Also Be Interested In